A venture capital firm based in USA has about one third of their investments in healthcare. The firm is a fairly opportunistic investor, and looks for companies that have a strong IP position and a strong management team. The firm invests opportunistically in therapeutics, medical devices, diagnostics and, to a lesser degree, digital health technologies, but they get most excited about companies leveraging new technologies and/or with the potential for platform business models. The firm generally invests in seed-series A rounds , investing $500k-3M in rounds generally in the range of $2 to $15 million. The firm prefers to invest companies that have some clinical data. The firm will invest globally, but prefers to invest in companies based in the US.
The firm invests opportunistically in therapeutics, medical devices, diagnostics and, to a lesser degree, digital health technologies. Historically, the firm has invested in health technologies driven by breakthroughs in AI, materials science or nanotechnology, and will not invest in a digital technology that does not have strong IP. The firm is generally agnostic to indication. The firm generally does not invest in consumer-facing/telehealth-related digital health companies.
The firm looks for companies with strong IP and management teams. The firm is willing to lead or co-invest, but will generally not participate in rounds larger than $30M. When acting as a lead investor, the firm is a very active investor, and plays a large role in helping company development.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Leave a Reply